These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32408390)

  • 1. Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study.
    Yavuz A; Kilinc MF; Aydin M; Ofluoglu Y; Bayar G
    Low Urin Tract Symptoms; 2021 Jan; 13(1):17-21. PubMed ID: 32408390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Tamsulosin, Oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms.
    Maldonado-Avila M; Garduno-Arteaga L; Jungfermann-Guzman R; Manzanilla-Garcia HA; Rosas-Nava E; Procuna-Hernandez N; Vela-Mollinedo A; Almazan-Trevino L; Guzman-Esquivel J
    Int Braz J Urol; 2016; 42(3):487-93. PubMed ID: 27286111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunction of tamsulosin or mirabegron before semi-rigid ureterolithotripsy improves outcomes: prospective, randomized single-blind study.
    Bayar G; Kilinc MF; Yavuz A; Aydın M
    Int Urol Nephrol; 2019 Jun; 51(6):931-936. PubMed ID: 30989563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
    Sahin A; Yildirim C; Yuksel OH; Urkmez A
    Arch Esp Urol; 2020 Jan; 73(1):54-59. PubMed ID: 31950924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study.
    Tae BS; Cho S; Jeon BJ; Choi H; Park JY; Cho SY; Lee KC; Bae JH
    BJU Int; 2018 Nov; 122(5):866-872. PubMed ID: 29802800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
    Kaplan SA; Herschorn S; McVary KT; Staskin D; Chapple C; Foley S; Cambronero Santos J; Kristy RM; Choudhury N; Hairston J; Schermer CR
    J Urol; 2020 Jun; 203(6):1163-1171. PubMed ID: 31895002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial.
    Chandna A; Kumar S; Parmar KM; Sharma AP; Devana SK; Mete UK; Singh SK
    Urologia; 2022 Nov; 89(4):589-596. PubMed ID: 34596484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Mirabegron plus Tamsulosin and Tamsulosin Monotherapy for the Treatment of Ureteral Stent-Related Symptoms: A Prospective Randomized Study.
    Zhang K; Yan W; Li H; Chen J; Wang Q; Chai Y; Yuan L; Zhu G
    Urol Int; 2022; 106(12):1226-1232. PubMed ID: 36244331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial.
    Sivalingam S; Streeper NM; Sehgal PD; Sninsky BC; Best SL; Nakada SY
    J Urol; 2016 Feb; 195(2):385-90. PubMed ID: 26393904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.
    Herschorn S; McVary KT; Cambronero Santos J; Foley S; Kristy RM; Choudhury N; Hairston J; Kaplan SA
    Urology; 2021 Jan; 147():235-242. PubMed ID: 33045287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study.
    Katoh T; Kakizaki H; Lee KS; Ishida K; Katou D; Yamamoto O; Jong JJ; Sumarsono B; Uno S; Yamaguchi O
    Low Urin Tract Symptoms; 2021 Jan; 13(1):98-107. PubMed ID: 32975024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.
    Jian Z; Chen Y; Liu Q; Liao B; Yang T; Li H; Wang K
    World J Urol; 2019 Feb; 37(2):289-297. PubMed ID: 30030658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stent-related Symptoms: A Meta-analysis of Randomized Controlled Studies.
    Chen YB; Gao L; Jiang Q; Ran K; Luo RT
    Curr Med Sci; 2019 Oct; 39(5):707-718. PubMed ID: 31612387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.
    Liu S; Yu Y; Gao Y; Yang X; Pang Z
    Urolithiasis; 2016 Apr; 44(2):185-90. PubMed ID: 26242466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tamsulosin hydrochloride in relieving "double-J ureteral stent-related morbidity": a randomized placebo controlled clinical study.
    Singh I; Tripathy S; Agrawal V
    Int Urol Nephrol; 2014 Dec; 46(12):2279-83. PubMed ID: 25201459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial.
    Ragab M; Soliman MG; Tawfik A; Abdel Raheem A; El-Tatawy H; Abo Farha M; Magdy M; Elashry O
    Int Urol Nephrol; 2017 Jun; 49(6):961-966. PubMed ID: 28260223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms.
    Abdelaziz AS; Salama NM; Ghoneem AM
    World J Urol; 2022 Aug; 40(8):2113-2119. PubMed ID: 35760910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamsulosin Versus Mirabegron in Relieving Ureteric Stent-Related Symptoms: A Prospective, Double-Blinded, Randomized Controlled Trial.
    Javid M; Abdullah A; Ganapathy R; Gupta YB; Selvaraj S; Ilangovan AK; Sivalingam S; Prasad S
    Cureus; 2023 Dec; 15(12):e50502. PubMed ID: 38222169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of mirabegron on JJ stent-related symptoms: A multicentric study.
    Cinar O; Tanidir Y; Ozer S; Cizmeci S; Erbatu O; Ozdemir T; Girgin R; Ongun S; Ucer O; Kizilay F; Sen V; Irer B; Bozkurt O;
    Int J Clin Pract; 2021 Feb; 75(2):e13857. PubMed ID: 33230894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.